Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?

Related Experiment Videos

Afshan Siddiq1, Rafeeq Alam Khan, Sadia Ghousia Baig

  • 1Department of Pharmacology, Faculty of Pharmacy, University of Karachi, Karachi-75270, Pakistan.

Journal of Pharmacy & Bioallied Sciences
|June 21, 2011
PubMed

Insights

For Type II diabetes, controlling blood sugar alone doesn't eliminate coronary artery disease risk. Atorvastatin shows superior lipid-lowering and antidiabetic effects compared to biguanides, aiding cardiovascular disease risk reduction.

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Diabetic individuals face elevated coronary artery disease (CAD) risk due to increased lipoprotein levels.
  • While antidiabetic medications improve glycemic control in Type I diabetes, Type II diabetes mellitus patients may still have residual CAD risk despite improved lipid profiles.

Purpose of the Study:

  • To evaluate the efficacy of atorvastatin versus biguanides in managing dyslipidemia and cardiovascular risk in Type II diabetes mellitus.
  • To assess the combined lipid-lowering and antidiabetic effects of atorvastatin.

Main Methods:

  • Comparative study assessing atorvastatin against biguanides in diabetic patients.
  • Evaluation of lipid-lowering and glycemic control parameters.
  • Assessment of cardiovascular disease (CVD) risk reduction.

Main Results:

  • Atorvastatin demonstrated superior lipid-lowering capabilities compared to biguanides.
  • Atorvastatin exhibited significant antidiabetic activity.
  • The combination of lipid-lowering and antidiabetic effects suggests a greater potential for CVD risk reduction with atorvastatin.

Conclusions:

  • Atorvastatin is a more effective lipid-lowering agent than biguanides in Type II diabetes mellitus.
  • Atorvastatin's dual action on lipids and glycemic control makes it a valuable therapeutic option for reducing cardiovascular disease risk in diabetic patients.
Keywords:
3-hydroxy-3-methyl-glutaryl-CoA reductaseAtorvastatinbiguanidescardiovascular disorders

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...